PD-(L)1 x VEGF Bispecific Antibodies: Development Activity and Market Entry | Oncology Modality Intelligence

Description

List of Tables

No drug class in oncology is being contested as hard, or as expensively, as PD-(L)1XVEGF bispecific antibodies. The premise is direct: one molecule that does what pembrolizumab plus bevacizumab-style combinations do, with the convenience and synergy of a single construct. Akeso's ivonescimab turned that premise into the industry's central argument when its Chinese HARMONi-2 readout against pembrolizumab in PD-L1-positive lung cancer forced every major oncology company to answer the same question: is this the next backbone? The response was a deal wave. Summit Therapeutics took ivonescimab global and ran the HARMONi-3 program with Japanese sites among its geographies. BioNTech bought Biotheus outright for BNT327, then partnered the program with Bristol Myers Squibb in June 2025. Pfizer licensed SSGJ-707 from 3SBio in May 2025. Merck & Co took LM-299 from LaNova; Instil Bio took IMM2510 from ImmuneOnco. For Japan the questions are specific and unresolved. PMDA has not yet stated how it will weigh pivotal evidence generated largely in China; the class has no Japanese pricing precedent, and its reference point is the most heavily repriced product in Japanese history; and Japan's own majors must decide whether to in-license, build, or watch. Beneath the deal headlines sits a genuine scientific contest over construct design - avidity, geometry, Fc engineering - that will decide which molecules differentiate and which merely follow. This report organizes the class end to end: the biology and construct differences among the leading molecules, the full trial map from HARMONi through the BNT327 and SSGJ-707 programs, the deal structures that priced each asset, the regulatory-evidence question as it applies to Japan, and the pricing scenarios a pembrolizumab-competing bispecific would face under Japanese rules. It is written for oncology business-development teams on both sides of potential licenses, Japanese majors evaluating the class, investors holding or shorting the theme, and market-access planners who need the Japan answer before the filings arrive.

Scope and Coverage

The report covers the PD-(L)1XVEGF construct landscape, global trial programs including Japan enrollment, licensing and acquisition structures, PMDA evidentiary considerations for China-origin data, and Japanese pricing scenarios, with the pembrolizumab franchise as the reference frame.

Report Highlights

Construct and mechanism comparison across ivonescimab, BNT327, SSGJ-707, LM-299, and IMM2510
Full HARMONi program map, including Japan participation in HARMONi-3
The 2024-2025 deal wave: Summit, BioNTech/BMS, Pfizer/3SBio, Merck/LaNova, Instil/ImmuneOnco
PMDA's evidentiary expectations for China-origin pivotal data: precedents and open questions
Japanese pricing scenarios for a pembrolizumab-competing bispecific
In-licensing decision framework for Japanese majors evaluating the class

Product Code: JPH-101

Table of Content

1. Executive Summary

2. PD-(L)1 x VEGF Bispecific Antibodies: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

Akeso (CN) - ivonescimab originator; China approvals 2024 and 2025; HARMONi program co-sponsor
Summit Therapeutics (US) - ex-China ivonescimab licensee running the global HARMONi trials and the US filing strategy
BioNTech (DE) - BNT327 (pumitamig) acquired via the Biotheus transaction (Nov 2024); broad trial program
Bristol Myers Squibb (US) - BNT327 co-development and co-commercialization partner (Jun 2025)
Pfizer (US) - SSGJ-707 ex-China licensee (May 2025) with US manufacturing build-out
3SBio (CN) - SSGJ-707 originator on the CLF2 platform; China NSCLC, colorectal, and gynecologic trials
Merck & Co (US) - LM-299 PD-L1XVEGF licensed from LaNova (Nov 2024)
LaNova Medicines (CN) - LM-299 originator
ImmuneOnco (CN) - IMM2510 PD-L1XVEGF originator
Instil Bio (US) - IMM2510 ex-China licensee (2024)
Biotheus (CN) - BNT327 originator acquired by BioNTech

Product Code: JPH-101

List of Tables

Table 1. PD-(L)1XVEGF class overview: constructs, formats, and developers
Table 2. Ivonescimab design and the Akeso development program in China
Table 3. HARMONi-2 trial design: pembrolizumab comparison in PD-L1-positive NSCLC
Table 4. HARMONi-3 global trial structure, geographies, and Japan site participation
Table 5. HARMONi-6 and the broader Akeso/Summit indication expansion
Table 6. Summit Therapeutics licensing structure for ivonescimab ex-China rights
Table 7. BNT327 (pumitamig) construct design and the Biotheus origin
Table 8. BioNTech acquisition of Biotheus (2024): structure and strategic logic
Table 9. BioNTech-Bristol Myers Squibb BNT327 partnership (2025): scope and governance
Table 10. BNT327 global trial program by indication and region
Table 11. SSGJ-707 on the 3SBio CLF2 platform: design and China development plan
Table 12. Pfizer-3SBio license (2025): structure and US manufacturing build-out
Table 13. LM-299 and the Merck & Co license from LaNova (2024)
Table 14. IMM2510 and the Instil Bio license from ImmuneOnco (2024)
Table 15. Second-tier PD-(L)1XVEGF programs in China and the West
Table 16. Mechanistic rationale: VEGF biology in the tumor microenvironment and PD-(L)1 synergy
Table 17. Safety-classification questions for the class: VEGF-related events in combination constructs
Table 18. NSCLC treatment-landscape context for a new first-line backbone
Table 19. Indication-expansion logic beyond NSCLC: colorectal, gynecologic, and other tumors
Table 20. Combination strategies pairing PD-(L)1XVEGF backbones with ADCs
Table 21. China-origin pivotal data packages accepted by FDA and EMA: precedents
Table 22. PMDA treatment of China-origin and multiregional data: historical cases
Table 23. Japanese-site participation across class trial programs
Table 24. Japanese regulatory-consultation strategy for a PD-(L)1XVEGF filing
Table 25. Pembrolizumab franchise status in Japan: indications and repricing history
Table 26. NHI price-formation scenarios for a pembrolizumab-competing bispecific
Table 27. Market-expansion repricing exposure for a high-growth bispecific in Japan
Table 28. Comparator and cost-effectiveness arguments applicable to the class in Japan
Table 29. Japanese majors' IO portfolios and their exposure to a backbone shift
Table 30. In-licensing versus internal development options for Japanese companies
Table 31. Deal-term benchmark set for PD-(L)1XVEGF transactions, 2024-2025
Table 32. Manufacturing and CMC considerations for bispecific antibody production at scale
Table 33. CDMO capacity relevant to bispecific manufacturing for Japan supply
Table 34. Biomarker and PD-L1 testing considerations for class positioning in Japan
Table 35. Chinese regulatory pathway for class originators and its data implications
Table 36. US filing strategies for China-origin bispecifics: the Summit approach
Table 37. EU regulatory positioning for the class
Table 38. Scenario grid for class leadership: ivonescimab, BNT327, and SSGJ-707 paths
Table 39. Scenario grid for Japan market entry: filing sequences and partners
Table 40. Competitive-position matrix of class molecules for Japan
Table 41. Valuation-framework considerations for PD-(L)1XVEGF assets
Table 42. Risk register for ex-China licensees of class assets
Table 43. Risk register for Japanese companies standing outside the class
Table 44. Key opinion leader and society engagement landscape in Japanese thoracic oncology
Table 45. Trial-access infrastructure in Japan relevant to class enrollment
Table 46. Watchlist of class readouts and regulatory events, 2026-2028
Table 47. Partnering-question checklist for Japanese in-licensors
Table 48. Stakeholder map: originators, licensees, regulators, payers, and societies
Table 49. Historical analogies: prior backbone transitions in Japanese oncology practice
Table 50. Timeline of the PD-(L)1XVEGF class, 2022-2026

List of Figures

Figure 1. PD-(L)1XVEGF mechanism schematic: dual blockade in one construct
Figure 2. Class construct map by format and developer
Figure 3. Ivonescimab development arc from Akeso origin to global program
Figure 4. HARMONi program map with Japan participation highlighted
Figure 5. HARMONi-2 design schematic: the pembrolizumab comparison
Figure 6. Summit ex-China licensing structure diagram
Figure 7. Biotheus acquisition and BNT327 program integration at BioNTech
Figure 8. BioNTech-BMS partnership governance map (2025)
Figure 9. BNT327 global trial footprint
Figure 10. 3SBio CLF2 platform and SSGJ-707 design
Figure 11. Pfizer-3SBio transaction structure and manufacturing plan
Figure 12. Merck-LaNova and Instil-ImmuneOnco transaction map
Figure 13. Class deal timeline, 2024-2025
Figure 14. VEGF-safety considerations in bispecific constructs
Figure 15. NSCLC first-line treatment framework and the backbone question
Figure 16. Indication-expansion map beyond NSCLC
Figure 17. ADC-combination strategies on PD-(L)1XVEGF backbones
Figure 18. China-origin data acceptance precedents at FDA and EMA
Figure 19. PMDA data-expectation framework for multiregional and China-origin packages
Figure 20. Japanese-site enrollment footprint across class programs
Figure 21. Japan regulatory-consultation pathway for the class
Figure 22. Pembrolizumab Japan franchise and repricing history
Figure 23. NHI price-formation scenario tree for a class entrant
Figure 24. Market-expansion repricing exposure map
Figure 25. Cost-effectiveness argument structure for Japan assessment
Figure 26. Japanese majors' IO exposure to a backbone shift
Figure 27. In-license-versus-build decision tree for Japanese companies
Figure 28. Deal-term benchmarks across class transactions
Figure 29. Bispecific manufacturing and CMC critical path
Figure 30. CDMO network options for Japan supply
Figure 31. PD-L1 testing landscape and class positioning in Japan
Figure 32. China regulatory pathway for class originators
Figure 33. US filing strategy schematic for China-origin bispecifics
Figure 34. EU regulatory positioning map
Figure 35. Class-leadership scenario tree
Figure 36. Japan entry scenario tree: filings and partners
Figure 37. Competitive-position map of class molecules for Japan
Figure 38. Valuation-framework schematic for class assets
Figure 39. Risk map for ex-China licensees
Figure 40. Risk map for Japanese companies outside the class
Figure 41. Japanese thoracic-oncology KOL and society landscape
Figure 42. Trial-access infrastructure in Japan for class programs
Figure 43. Class readout and regulatory event calendar, 2026-2028
Figure 44. Partnering-question checklist for Japanese in-licensors
Figure 45. Stakeholder influence map across the class
Figure 46. Backbone-transition analogies in Japanese oncology history
Figure 47. Synergy-biology evidence map for dual PD-(L)1/VEGF blockade
Figure 48. Key-question tree for investors in the class
Figure 49. Key-question tree for BD teams evaluating the class
Figure 50. PD-(L)1XVEGF class timeline, 2022-2026

PD-(L)1 x VEGF Bispecific Antibodies: Development Activity and Market Entry | Oncology Modality Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. PD-(L)1 x VEGF Bispecific Antibodies: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures